Otolaryngology

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia Alnylam Pharmaceuticals.

ALN-PCS is an RNAi therapeutic that utilizes proprietary Alnylam second-era lipid nanoparticle technology, the MC3 lipid specifically. ALN-PCS is Alnylam’s 4th RNAi therapeutic to enter clinical development, highlighting our continued commitment and concentrate on advancement of breakthrough medicines to patients. This milestone also exemplifies our ongoing changeover from ‘platform organization’ to ‘product organization’, said John …

Enter soybean oil a new role Health And Beauty click here.

Enter soybean oil a new role Health And Beauty.Scientists have to develop a new method for converting soybean oil into a highly effective bio-based sunscreen active ingredient that reports neither the potential health concerns of ingredients in some existing sunscreens The new, natural sunscreens could replace petroleum-derived ingredients in a variety of personal care products, …

Item: Not enough nitric oxide bioavailability: a hypothesis.

Item: Not enough nitric oxide bioavailability: a hypothesis, to avoid adverse effects of transfusion to explain to explain. John D. Robert Neuman, Arshed Quyyumi and Roy Sutliff. ;; Published Online: April 15, 2014 . Item: Microparticles in Stored Red Blood Cells as potential mediators of transfusion complications. Jy Jy, Marco Ricci, Sherry Shariatmadar, Orlando Gomez …